S
Susan Halabi
Researcher at Duke University
Publications - 403
Citations - 25225
Susan Halabi is an academic researcher from Duke University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 66, co-authored 351 publications receiving 21940 citations. Previous affiliations of Susan Halabi include European Organisation for Research and Treatment of Cancer & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I. Scher,Susan Halabi,Ian F. Tannock,Michael J. Morris,Cora N. Sternberg,Michael A. Carducci,Mario A. Eisenberger,Celestia S. Higano,Glenn J. Bubley,Robert Dreicer,Daniel P. Petrylak,Philip W. Kantoff,Ethan Basch,William Kevin Kelly,William D. Figg,Eric J. Small,Tomasz M. Beer,George Wilding,Alison Martin,Maha Hussain +19 more
TL;DR: New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
Journal ArticleDOI
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Robert S. Sandler,Susan Halabi,John A. Baron,Susan Budinger,Electra D. Paskett,Roger Keresztes,Nicholas J. Petrelli,J. Marc Pipas,Daniel D. Karp,Charles L. Loprinzi,Gideon Steinbach,Richard L. Schilsky +11 more
TL;DR: In this paper, the authors conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas, which was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis.
Journal ArticleDOI
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley,Michael A. Carducci,William L. Dahut,Nancy A. Dawson,Danai Daliani,Mario A. Eisenberger,William D. Figg,Boris Freidlin,Susan Halabi,Gary R. Hudes,Maha Hussain,Richard Kaplan,Charles E. Myers,William Oh,Daniel P. Petrylak,Eddie Reed,Bruce J. Roth,Oliver Sartor,Howard I. Scher,Jonathan W. Simons,V. J. Sinibaldi,Eric J. Small,Matthew R. Smith,Donald L. Trump,Robin T. Vollmer,George Wilding +25 more
TL;DR: The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.
Journal ArticleDOI
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher,Michael J. Morris,Walter M. Stadler,Celestia S. Higano,Ethan Basch,Karim Fizazi,Emmanuel S. Antonarakis,Tomasz M. Beer,Michael A. Carducci,Kim N. Chi,Paul G. Corn,Johann S. de Bono,Robert Dreicer,Daniel J. George,Elisabeth I. Heath,Maha Hussain,Wm. Kevin Kelly,Glenn Liu,Christopher J. Logothetis,David M. Nanus,Mark N. Stein,Dana E. Rathkopf,Susan F. Slovin,Charles J. Ryan,Oliver Sartor,Eric J. Small,Matthew R. Smith,Cora N. Sternberg,Mary-Ellen Taplin,George Wilding,Peter S. Nelson,Lawrence H. Schwartz,Susan Halabi,Philip W. Kantoff,Andrew J. Armstrong +34 more
TL;DR: The concept of no longer clinically benefiting is introduced to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions.
Journal ArticleDOI
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Philip W. Kantoff,Susan Halabi,Mark R. Conaway,Joel Picus,Jeffrey J. Kirshner,Vera Hars,Donald L. Trump,Eric P. Winer,Nicholas J. Vogelzang +8 more
TL;DR: M+H generated more frequent responses and a delay in both time to treatment failure and disease progression compared with hydrocortisone alone, and there was an indication that QOL was better with M+H, in particular with respect to pain control.